Axol Introduces Steve Rees as Scientific Advisory Board Member
News Jan 21, 2016
Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, has announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB). Dr Rees will be attending the fifth annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA from 23-27 January 2016, where Axol will showcase the newest addition to its growing range of primary and induced pluripotent stem cell (iPSC)-derived cells for drug discovery through several poster presentations and an exhibitor tutorial.
Axol Announces Steve Rees as Scientific Advisory Board Member
Steve Rees is President of Screening Sciences and Sample Management, AstraZeneca, sits on the Board of Directors, European Laboratory Robotics Interest Group (ELRIG) and is a member of the Europe Council, SLAS. A renowned expert amongst the drug discovery community, Dr Rees will guide Axol in developing and validating products that are in line with current industry trends and aid the company in bringing cutting-edge solutions to its customers.
Dr Rees, SAB Member, Axol Bioscience commented, ‘SLAS is a very collaborative culture and of great value in terms of networking and learning best practice about state-of-the-art technologies in the field of drug discovery and laboratory automation from like-minded scientists. Dr Yichen Shi, CEO, Axol Bioscience said, ‘With Dr Rees as a member of Axol’s SAB, we look forward to collaborating on future projects to develop solutions that could help us enhance our ability to discover drugs in future.’
Axol Expands Range of Primary and iPSC-Derived Cells
Axol who already offers a number of primary and iPSC-derived cells from healthy and patient donors, will be showcasing the latest addition to these ranges. This includes the launch of:
Assay-Ready Expanded (ARE) Hepatocytes Highly characterized and validated hepatocytes that are qualified for CYP induction, metabolism studies and micronucleus genotoxicity assays. Axol ARE Hepatocytes are available in large batch sizes, meaning they offer a reliable source of hepatocytes from the same donor for consistency from preliminary experiments to high-throughput screening. The Axol ARE range also comes complete with thawing and assay culture media for optimal revival, maintenance and viability of liver cells.
iPSC-Derived Astrocytes Mature astrocytes and progenitor cells derived from integration-free human iPSCs are ready-to-use, easy-to-differentiate and allow scientists to build physiologically relevant cellular models in vitro for neurotoxicity testing and drug screening.
Isogenic Central Nervous System (CNS) Disease-Specific Knockouts Axol has expanded its collection of isogenic CNS disease-specific neural stem cells to include Parkinson’s disease, amyotrophic lateral sclerosis (ALS), schizophrenia, autism and additional Alzheimer’s disease mutations. The extended range offers researchers a readily accessible source of knockout lines to investigate the functional effect of several genes implicated in dopaminergic neuron dysfunction.
Axol Stem Cell Experts Present at SLAS 2016
The Axol Exhibitor Tutorial will be held on 26 January 2016 from 2:00-2:45pm in Room 3. Dr Alfredo Cabrera, Scientist, Janssen Pharmaceutica will present ‘Modelling Alzheimer’s Disease: A High Throughput-Compatible Assay for Detecting TAU Aggregation Using iPSC-Derived Cortical Neurons’. Dr Cabrera will also present a poster (#5023) on this topic on 25 January 2016 from 1:00-3:00pm.
Dr Priyanka Dutta-Passecker, Business Development Manager, Axol Bioscience will present ‘Serum-free human iPSC-derived cardiomyocytes for contactless in vitro testing’ (poster #2097) on 25 January 2016 from 1:00-3:00pm and ‘Characterization and potential applications of human iPSC-derived neural stem cells’ (poster #2090) on 26 January 2016 from 1:00-3:00pm.
Axol invites all SLAS 2016 attendees wanting to discover more about how its range of human cell culture products and services can be used in drug discovery applications to visit booth #1655, exhibitor tutorial and poster presentation sessions.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE